

## CORRECTION OPEN



## Correction: Discriminative binding of tau PET tracers PI2620, MK6240 and RO948 in Alzheimer's disease, corticobasal degeneration and progressive supranuclear palsy brains

Mona-Lisa Malarte, Per-Göran Gillberg, Amit Kumar , Nenad Bogdanovic , Laëtitia Lemoine and Agneta Nordberg

© The Author(s) 2023

Molecular Psychiatry; <https://doi.org/10.1038/s41380-023-02021-2>Correction to: *Molecular Psychiatry* <https://doi.org/10.1038/s41380-022-01875-2>, published online 29 November 2022

After our manuscript has been published online, we identified an error in our semi-quantification values presented in Table 2 of the manuscript, due to an error in the tritium standard reference date. To calculate the amount of tracer bound in fmol/mg, we prepare the linear standard curve using the commercially available tritium standards ranging from 0 to 489.1uCi/g. Since tritium has a half-life of 12.33 years, to know the percentage of activity remaining and respective calculation of fmol/mg, we need to take into consideration the manufacturing date of tritium standards, which was unfortunately mixed up in one of our analysis's files. Instead of year 2010, we used year 2018 in one file. We have now re-performed the analyses with the correct reference date. The new values are in the same range (see correction in the revised ms and Table 2) and comparable to the published ones. This erratum does not change the final results, interpretation and overall conclusions of the paper

but for the sake of accuracy and transparency, we rectified Table 2 and sincerely apologize. The corrected Table 2 is attached.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2023

**Table 2.** Comparative  $^3\text{H}$ -PI2620 and  $^3\text{H}$ -MK6240 binding studies expressed as total (fmol/mg), non-specific (NSP; fmol/mg) and specific (fmol/mg and %) binding in small frozen sections from CBD and PSP brains.

Diagnostic group	TOTAL (fmol/mg)		NSP (fmol/mg)		Specific (fmol/mg)		Specific (%)	
	$^3\text{H}$ -PI2620	$^3\text{H}$ -MK6240	$^3\text{H}$ -PI2620	$^3\text{H}$ -MK6240	$^3\text{H}$ -PI2620	$^3\text{H}$ -MK6240	$^3\text{H}$ -PI2620	$^3\text{H}$ -MK6240
CBD 20	47.6	39.1	19.9	29.9	27.6	9.2	58.1	23.6
CBD 22	71.3	44.5	16.5	51.3	54.9	0.0	76.9	0.0
CBD 23	87.6	69.7	25.3	49.8	62.3	19.9	71.1	28.6
PSP 27	47.2	35.6	12.3	29.1	34.9	6.5	73.9	18.4
PSP 28	46.3	39.1	26.0	34.5	20.3	4.6	43.9	11.8

CBD cortico basal degeneration, PSP progressive supranuclear palsy.